Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard is removing its women’s pelvic organ prolapse and stress urinary incontinence mesh devices from the European Market, according to a recently posted field corrective action from the company.
The Murray Hill, N.J.-based company said that it is “initiating a cease in production and distribution of these devices and a removal of these products from hospitals and distribution centers with immediate effect,” according to the notice.
The removal of the devices was not a result of safety concerns, Bard clarified, adding that patients with such devices do not require any follow-up activities.
In the letter, Bard instructed individuals with affected devices to locate and quarantine them and to notify anyone who the products have been distributed to so that the devices could be appropriately returned.
The company again reiterated that implanted devices are not affected by the recall, and that no additional activities are required for patients with the meshes.
In January, Bard and subsidiary Davol won an appeal in a lawsuit involving a woman who died a year after having a Bard surgical mesh patch implanted to repair a hernia.